Life Sciences, deals, stock

Idenix to Raise $21.2 M in SPO

Eric Hal Schwartz 8/6/09

Idenix Pharmaceuticals (NASDAQ:IDIX), a Cambridge, MA-based developer of anti-viral drugs, announced today in a press release that it has priced a secondary public offering of 7.25 million shares at $3.14 each. Idenix expects to raise $21.2 million from the offer, which is expected to close on August 10, after processing fees and other costs. The company is currently developing treatments for Hepatitis C.

Eric Hal Schwartz is an intern in Xconomy's Seattle office. He can be reached at eschwartz@xconomy.com.